Q-omics provides the consensus-scored ARHGEF7 profile across patient tissues and cancer cell-line models. ARHGEF7 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ARHGEF7 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, ARHGEF7 protein abundance shows 33,657 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where ARHGEF7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARHGEF7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARHGEF7 survival associations across molecular data types. ARHGEF7 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARHGEF7 RNA expression–survival associations across cancer types. High ARHGEF7 expression shows unfavorable associations in ACC, UVM, CESC and HNSC, but favorable associations in KIRC and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ARHGEF7 RNA expression.
This table summarizes ARHGEF7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ARHGEF7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARHGEF7 shows lower tumor expression in THCA and BRCA and higher tumor expression in KIRC, HNSC, COAD and LIHC. The KIRC box plot shows higher ARHGEF7 RNA expression in tumor versus normal tissue (log2 FC = +0.953, t-test p < 0.001).
This table shows molecular features associated with ARHGEF7 in patient tissues and cancer cell lines. In patient samples, ARHGEF7 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ARHGEF7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
